The contractor shall be the liaison, prepare study materials and forms, train staff, follow-up with study participants, conduct screenings, provide a diagnosis and treatment procedures for cervical…

Active Indefinite Delivery Contract Awarded Last action

Contract number
75N91024D00014
Awardee
Awarding agency
Task orders
2 $9,773,449 obligated

Award facts

Opportunity
Combined order value
  • $9,773,449 Current, with exercised options
  • $14,019,255 Potential, with all options
Last date to order 21% complete
IDV ceiling 20% used
$49,000,000.00
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Cancer Institute awarded a single-award indefinite-delivery contract to Fundacion Inciensa on September 1, 2024, with a ceiling of $49 million and ultimate completion date of August 31, 2034. The contract carries no set-aside designation.

Work is performed in Costa Rica. The IDIQ procures epidemiological, clinical, and laboratory research services in support of long-term HPV vaccine clinical trials and disease prevention studies. Contractor responsibilities include serving as study liaison, preparing study materials and forms, training staff, screening and recruiting participants, conducting follow-up activities, providing diagnosis and treatment procedures for cervical disease, collecting and processing biospecimens, and managing study data. The effort encompasses continuation of follow-up on over 35,000 existing trial participants and potential expansion to evaluate other pathogens including SARS-CoV-2.

The originating pre-solicitation was posted December 4, 2023, with questions due December 18, 2023. Primary NAICS is 541715 (Research and Development in the Physical, Engineering, and Life Sciences); PSC is R425.

Two delivery orders have been issued under this IDIQ. An initial $2,808 kick-off order was awarded September 1, 2024, with completion by September 30, 2024. A second delivery order valued at $20,168,469 was awarded March 26, 2025, extending the ESCUDDO HPV vaccine durability study from five years to 7.5 years (ESCUDDO-7) to evaluate protection afforded by one versus two vaccine doses, with completion by September 15, 2028. Both delivery orders are firm fixed-price with no set-aside.

Description

The contractor shall be the liaison, prepare study materials and forms, train staff, follow-up with study participants, conduct screenings, provide a diagnosis and treatment procedures for cervical disease, enter and maintain data, collect biospecime

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00001 · EO14398 epidemiology and prevention of infections and related diseases $0
Original award $0

Quick answers

Who was awarded contract 75N91024D00014?

75N91024D00014 was awarded to Fundacion Inciensa by National Cancer Institute (National Institutes of Health) on September 1, 2024.

How much is contract 75N91024D00014 worth?

Orders under 75N91024D00014 have obligated $9,773,449. Their combined potential value, with all options, is $14,019,255. 75N91024D00014's own ceiling is $49,000,000.

How many orders have been placed under contract 75N91024D00014?

2 orders have been placed under 75N91024D00014, the latest on March 26, 2025.

Who can order from contract 75N91024D00014?

75N91024D00014 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75N91024D00014 competed?

The extent of competition for 75N91024D00014 was full and open competition. The government received 2 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV